| MeSH term | MeSH ID | Detail |
|---|---|---|
| Acute Pain | D059787 | 3 associated lipids |
| Acute Lung Injury | D055371 | 33 associated lipids |
| Fetal Nutrition Disorders | D048070 | 1 associated lipids |
| Ganglion Cysts | D045888 | 1 associated lipids |
| Hypoxia-Ischemia, Brain | D020925 | 22 associated lipids |
| Parkinsonian Disorders | D020734 | 20 associated lipids |
| Neurodegenerative Diseases | D019636 | 32 associated lipids |
| Cholangiocarcinoma | D018281 | 7 associated lipids |
| Dermatitis, Allergic Contact | D017449 | 20 associated lipids |
| Endometrial Neoplasms | D016889 | 30 associated lipids |
2-arachidonoylglycerol
2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.
Cross Reference
Introduction
To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 2-arachidonoylglycerol?
2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol
PubChem Associated disorders and diseases
What pathways are associated with 2-arachidonoylglycerol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 2-arachidonoylglycerol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 2-arachidonoylglycerol?
Knock-out
Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with 2-arachidonoylglycerol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Szabo B et al. | Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. | 2006 | J. Physiol. (Lond.) | pmid:16973696 |
| Kasai HF et al. | Studies on high-energy collision-induced dissociation of endogenous cannabinoids: 2-arachidonoylglycerol and n-arachidonoylethanolamide in FAB-mass spectrometry. | 2006 | Anal Sci | pmid:16837740 |
| Matias I et al. | Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. | 2006 | Int J Obes (Lond) | pmid:16570107 |
| Matias I et al. | Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. | 2006 | Prostaglandins Leukot. Essent. Fatty Acids | pmid:17011761 |
| Bari M et al. | Effect of lipid rafts on Cb2 receptor signaling and 2-arachidonoyl-glycerol metabolism in human immune cells. | 2006 | J. Immunol. | pmid:17015679 |
| Spoto B et al. | Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. | 2006 | Biochimie | pmid:16949718 |
| Wagner JA et al. | 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. | 2006 | J. Cardiovasc. Pharmacol. | pmid:16775503 |
| Quistad GB et al. | Monoacylglycerol lipase inhibition by organophosphorus compounds leads to elevation of brain 2-arachidonoylglycerol and the associated hypomotility in mice. | 2006 | Toxicol. Appl. Pharmacol. | pmid:16310817 |
| van der Stelt M et al. | Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. | 2006 | Cell. Mol. Life Sci. | pmid:16732431 |
| Panikashvili D et al. | The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. | 2006 | Neurobiol. Dis. | pmid:16364651 |
| Parkkari T et al. | Synthesis and CB1 receptor activities of dimethylheptyl derivatives of 2-arachidonoyl glycerol (2-AG) and 2-arachidonyl glyceryl ether (2-AGE). | 2006 | Bioorg. Med. Chem. | pmid:16403642 |
| Avraham Y et al. | Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. | 2006 | Neurobiol. Dis. | pmid:16102970 |
| Saario SM et al. | URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain. | 2006 | Chem. Biol. | pmid:16931330 |
| Sang N et al. | PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. | 2006 | J. Physiol. (Lond.) | pmid:16484297 |
| Parkkari T et al. | Alpha-methylated derivatives of 2-arachidonoyl glycerol: synthesis, CB1 receptor activity, and enzymatic stability. | 2006 | Bioorg. Med. Chem. Lett. | pmid:16466915 |
| Kurihara R et al. | Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. | 2006 | J. Biol. Chem. | pmid:16513651 |
| Mestre L et al. | The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. | 2006 | Biochem. Pharmacol. | pmid:16914119 |
| Blüher M et al. | Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. | 2006 | Diabetes | pmid:17065342 |
| Oka S et al. | Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. | 2006 | J. Immunol. | pmid:17142782 |
| Yoshida T et al. | Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. | 2006 | J. Neurosci. | pmid:16672646 |
| Sugiura T et al. | Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. | 2006 | Prog. Lipid Res. | pmid:16678907 |
| Katona I et al. | Molecular composition of the endocannabinoid system at glutamatergic synapses. | 2006 | J. Neurosci. | pmid:16723519 |
| Shiga N et al. | Elimination of 2-arachidonoylglycerol action by direct hemoperfusion through immobilized polymyxin B fibers: an experimental study in conscious guinea pigs. | 2006 | Ther Apher Dial | pmid:17199882 |
| McCarron RM et al. | Endothelial-mediated regulation of cerebral microcirculation. | 2006 | J. Physiol. Pharmacol. | pmid:17244945 |
| Parrish JC and Nichols DE | Serotonin 5-HT(2A) receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism. | 2006 | J. Neurochem. | pmid:17010161 |
| Kurabayashi M et al. | 2-Arachidonoylglycerol increases in ischemia-reperfusion injury of the rat liver. | 2005 Jan-Feb | J Invest Surg | pmid:15804949 |
| Lambert DM and Fowler CJ | The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. | 2005 | J. Med. Chem. | pmid:16078824 |
| Hayase T et al. | Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. | 2005 | Behav Pharmacol | pmid:16148444 |
| Venderova K et al. | Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. | 2005 | Exp. Neurol. | pmid:15899265 |
| Hohmann AG et al. | An endocannabinoid mechanism for stress-induced analgesia. | 2005 | Nature | pmid:15973410 |
| Sancho R et al. | Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. | 2005 | J. Immunol. | pmid:16148147 |
| Lauckner JE et al. | The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. | 2005 | Proc. Natl. Acad. Sci. U.S.A. | pmid:16365309 |
| Gokoh M et al. | 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. | 2005 | FEBS Lett. | pmid:16288744 |
| Straiker A and Mackie K | Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. | 2005 | J. Physiol. (Lond.) | pmid:16179366 |
| Iturralde M et al. | Characterization of the lipolytic pathways that mediate free fatty acid release during Fas/CD95-induced apoptosis. | 2005 | Apoptosis | pmid:16215685 |
| Engeli S et al. | Activation of the peripheral endocannabinoid system in human obesity. | 2005 | Diabetes | pmid:16186383 |
| Safo PK and Regehr WG | Endocannabinoids control the induction of cerebellar LTD. | 2005 | Neuron | pmid:16301180 |
| Alger BE | Endocannabinoid identification in the brain: studies of breakdown lead to breakthrough, and there may be NO hope. | 2005 | Sci. STKE | pmid:16278487 |
| Rademacher DJ et al. | Waterborne lead exposure affects brain endocannabinoid content in male but not female fathead minnows (Pimephales promelas). | 2005 | Neurotoxicology | pmid:15527869 |
| Shoemaker JL et al. | Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. | 2005 | J. Pharmacol. Exp. Ther. | pmid:16081674 |
| Jung KM et al. | Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. | 2005 | Mol. Pharmacol. | pmid:16051747 |
| Makara JK et al. | Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. | 2005 | Nat. Neurosci. | pmid:16116451 |
| Ligresti A et al. | Endocannabinoid metabolic pathways and enzymes. | 2005 | Curr Drug Targets CNS Neurol Disord | pmid:16375679 |
| Di S et al. | Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. | 2005 | J. Physiol. (Lond.) | pmid:16239276 |
| Gauthier KM et al. | Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. | 2005 | Am. J. Physiol. Heart Circ. Physiol. | pmid:15528233 |
| Gabbay E et al. | Endocannabinoids and liver disease--review. | 2005 | Liver Int. | pmid:16162147 |
| Cabranes A et al. | Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. | 2005 | Neurobiol. Dis. | pmid:16242629 |
| Wagner JA et al. | Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts. | 2005 | J. Cardiovasc. Pharmacol. | pmid:16116341 |
| McPartland JM et al. | Cannabimimetic effects of osteopathic manipulative treatment. | 2005 | J Am Osteopath Assoc | pmid:16118355 |
| Wahn H et al. | The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. | 2005 | Am. J. Physiol. Heart Circ. Physiol. | pmid:16055511 |